The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the promising updates in lymphoma at ASH 2019?

Dec 16, 2019
Share:

During the 61st American Society of Hematology (ASH) meeting, Orlando, US, the Lymphoma Hub were pleased to host a discussion between Nathan Fowler and Michael Wang, both from the MD Anderson Cancer Center, Houston, US, on what are the promising updates in lymphoma at ASH 2019?

Nathan Fowler and Michael Wang discuss the results from the pivotal, multicenter, ZUMA-2 trial that investigated the use of CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed or refractory mantle cell lymphoma. They also discuss updates from the tazemetostat trial and talked about data from a study that combined lenalidomide and obinutuzumab to treat patients with follicular lymphoma in both the frontline and relapsed setting.

What are the promising updates in lymphoma at ASH 2019?

Share: